As of November 14, 2026, RAPT Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 3, 2026 (Form 8-K, March 3, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like RAPT Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
RAPT Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-03. Every row below is cited to the filing it comes from, and this page adds each new change as RAPT Therapeutics, Inc. files it.
Layoffs on record: about 47 jobs, latest 2024-07-19 (layoff filings and notices).
Also on the record for RAPT Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by ORBIMED ADVISORS LLC | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RTW Investments, LP | 5.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 0.4% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by Glazer Capital, LLC | 5.36% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BIOTECHNOLOGY VALUE FUND L P | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 3.77% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by ORBIMED ADVISORS LLC | 6.6% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.2% of the class | 5%+ stakes | Source |
| October 29, 2025 | Stake report, Schedule 13G, by ForGrowth III PA B.V. | 7.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 5.75% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs RAPT Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on RAPT Therapeutics, Inc. and the records around it.
The people at RAPT Therapeutics, Inc.
- William Rieflin is also named on 1 other Form D filing: Lycia Therapeutics, Inc. (Jun 2026)
RAPT Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Watch RAPT Therapeutics, Inc.
Get an email when RAPT Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on RAPT Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on RAPT Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on RAPT Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-03 | Reported | not named in the filing | 8-K, 2026-03-03 |
New leaders reset buying decisions — get the Full Report on RAPT Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at RAPT Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at RAPT Therapeutics, Inc.Every change, in the filing's words
Reported
In accordance with the terms of the Merger Agreement, at the Effective Time (i) each of Brian Wong, Michael Giordano, Mary Ann Gray, Linda Kozick, Lori Lyons-Williams, Scott Braunstein and Ashley Dombkowski resigned from his or her respective position as a member of the Company's board of directors, including from any and all committees thereof, and (ii) Kevin Ryan and Justin Tze-Chieh Huang, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company.
- Effective immediately following completion of the Merger, all of the incumbent officers of the Company, as of immediately prior to the Effective Time, were removed as officers of the Company.
- Following the Effective Time, the officers of the Company are as follows: Kevin Ryan as Vice President and Treasurer, Justin Tze-Chieh Huang as President and Secretary and Hatixhe Hoxha as Assistant Secretary.
Tools for this story
Each opens in a new tab, filled in for RAPT Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
